Biblio
[Clinical analysis of sirolimus as an alternative GVHD prophylaxis for patients with kidney injury undergoing allo-HSCT]. Zhonghua Nei Ke Za Zhi. 2023;62(12):1444-1450.
[Clinical features and risk factors for invasive fungal sinusitis after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(1):22-27.
[Clinical implication of minimal residue disease monitoring by WT1 gene detection and flow cytometry in myelodysplastic syndrome with allogeneic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2018;39(12):998-1003.
. [The effect of glucose-6-phosphate dehydrogenase deficiency on allogeneic hematopoietic stem cell transplantation in patients with hematological disorders]. Zhonghua Xue Ye Xue Za Zhi. 2024;45(2):121-127.
[Effect of sirolimus combined with anti-CD20 monoclonal antibody desensitization on the prognosis of patients underwent haploidentical stem cell transplantation]. Zhonghua Yi Xue Za Zhi. 2024;104(11):843-849.
[Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk]. Zhonghua Xue Ye Xue Za Zhi. 2019;40(7):554-560.
[Risk factors analysis for steroid-resistant acute graft versus host disease after haploidentical hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2020;41(2):106-111.
[Safety of rabbit anti-human thymocyte immunoglobulin in second allogeneic hematopoietic stem cell transplantation for patients with hematological diseases]. Zhonghua Xue Ye Xue Za Zhi. 2022;43(10):853-857.
[Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2023;44(2):124-131.